Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA Article

Full Text via DOI: 10.1007/s13300-018-0413-5 PMID: 29600507 Web of Science: 000434169400034
Open Access Industry Collaboration International Collaboration

Cited authors

  • Blonde, Lawrence; Meneghini, Luigi; Peng, Xuejun Victor; Boss, Anders; Rhee, Kyu; Shaunik, Alka; Kumar, Supriya; Balodi, Sidhartha; Brulle-Wohlhueter, Claire; McCrimmon, Rory J.

Abstract

  • Introduction: Basal insulin (BI) plays an important role in treating type 2 diabetes (T2D), especially when oral antidiabetic (OAD) medications are insufficient for glycemic control. We conducted a retrospective, observational study using electronic medical records (EMR) data from the IBM (R) Explorys database to evaluate the probability of achieving glycemic control over 24 months after BI initiation in patients with T2D in the USA.; Methods: A cohort of 6597 patients with T2D who started BI following OAD(s) and had at least one valid glycated hemoglobin (HbAlc) result recorded both within 90 days before and 720 days after BI initiation were selected. We estimated the changes from baseline in HbAlc every 6 months, the quarterly conditional probabilities of reaching HbAlc < 7% if a patient had not achieved glycemic control prior to each quarter (Q), and the cumulative probability of reaching glycemic control over 24 months.; Results: Our cohort was representative of patients with T2D who initiated BI from OADs in the USA. The average HbAlc was 9.1% at BI initiation, and decreased robustly (1.5%) in the first 6 months after initiation with no further reductions thereafter. The conditional probability of reaching glycemic control decreased rapidly in the first year (26.6% in Q2; 17.6% in Q3; 8.6% in Q4), and then remained low (<= 6.1%) for each quarter in the second year. Cumulatively, about 38% of patients reached HbAlc < 7% in the first year; only approximately 8% more did so in the second year.; Conclusion: Our study of real-world data from a large US EMR database suggested that among patients with T2D who initiated BI after OADs, the likelihood of reaching glycemic control diminished over time, and remained low from 12 months onwards. Additional treatment options should be considered if patients do not reach glycemic control within 12 months of BI initiation.

Authors

Publication date

  • 2018

Published in

International Standard Serial Number (ISSN)

  • 1869-6953

Start page

  • 1347

End page

  • 1358

Volume

  • 9

Issue

  • 3